Literature DB >> 8384809

Azithromycin, rifabutin, and rifapentine for treatment and prophylaxis of Mycobacterium avium complex in rats treated with cyclosporine.

S T Brown1, F F Edwards, E M Bernard, W Tong, D Armstrong.   

Abstract

Azithromycin, rifabutin, and rifapentine were used to treat or prevent disseminated Mycobacterium avium complex (MAC) infections produced in rats immunosuppressed with cyclosporine. Animals with bacteremic infections were treated 1 week after intravenous inoculation with 10(7) CFU of MAC with azithromycin, 100 mg/kg of body weight administered subcutaneously for 5 days and then 75 mg/kg on Monday, Wednesday, and Friday, or with rifabutin or rifapentine, 20 mg/kg administered intraperitoneally on Monday through Friday. All three drugs showed efficacy after 1 and 2 months. Rifabutin cleared the organisms from tissues more rapidly than azithromycin or rifapentine. To approximate prophylaxis, treatment was started 2 weeks before intravenous inoculation with 10(4) organisms. MAC infections were undetectable in treated animals after 4 months, while control animals had disseminated infections. These findings support the rationale for clinical trials of treatment and prophylaxis with these agents. The cyclosporine-treated rat appears to be a useful model in which to evaluate compounds for the treatment and prophylaxis of disseminated MAC infections.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8384809      PMCID： PMC187683          DOI： 10.1128/AAC.37.3.398

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Effect of combined clofazimine and ansamycin therapy on Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS.

Authors:  H Masur; C Tuazon; V Gill; G Grimes; B Baird; A S Fauci; H C Lane
Journal:  J Infect Dis       Date:  1987-01       Impact factor: 5.226

2.  The effects of erythromycin in patients treated with cyclosporine.

Authors:  R Martell; D Heinrichs; C R Stiller; M Jenner; P A Keown; J Dupre
Journal:  Ann Intern Med       Date:  1986-05       Impact factor: 25.391

Review 3.  Mycobacterium avium complex infection.

Authors:  L S Young
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

4.  In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige mice.

Authors:  P R Gangadharam; V K Perumal; N R Podapati; L Kesavalu; M D Iseman
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

5.  Comprehensive approach to identification of serovars of Mycobacterium avium complex.

Authors:  J C Denner; A Y Tsang; D Chatterjee; P J Brennan
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

Review 6.  Adverse reactions and interactions of cyclosporin.

Authors:  J P Scott; T W Higenbottam
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Mar-Apr

7.  Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution.

Authors:  A E Girard; D Girard; A R English; T D Gootz; C R Cimochowski; J A Faiella; S L Haskell; J A Retsema
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

8.  The use of DNA probes identifying restriction-fragment-length polymorphisms to examine the Mycobacterium avium complex.

Authors:  J J McFadden; P D Butcher; J Thompson; R Chiodini; J Hermon-Taylor
Journal:  Mol Microbiol       Date:  1987-11       Impact factor: 3.501

9.  Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome.

Authors:  C C Hawkins; J W Gold; E Whimbey; T E Kiehn; P Brannon; R Cammarata; A E Brown; D Armstrong
Journal:  Ann Intern Med       Date:  1986-08       Impact factor: 25.391

10.  Continuous high-grade mycobacterium avium-intracellulare bacteremia in patients with the acquired immune deficiency syndrome.

Authors:  B Wong; F F Edwards; T E Kiehn; E Whimbey; H Donnelly; E M Bernard; J W Gold; D Armstrong
Journal:  Am J Med       Date:  1985-01       Impact factor: 4.965
View more
  9 in total

1.  Rifapentine is active in vitro and in vivo against Toxoplasma gondii.

Authors:  F G Araujo; A A Khan; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

2.  Drug evaluation of concurrent Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium complex infections in a rat model.

Authors:  M Brun-Pascaud; P Rajagopalan-Levasseur; F Chau; G Bertrand; L Garry; F Derouin; P M Girard
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

3.  Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection.

Authors:  Y K Oh; D E Nix; R M Straubinger
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

4.  Activity of KRM 1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection.

Authors:  L E Bermudez; P Kolonoski; L S Young; C B Inderlied
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

5.  Pharmacokinetics, toxicity, and efficacy of liposomal capreomycin in disseminated Mycobacterium avium beige mouse model.

Authors:  P Le Conte; F Le Gallou; G Potel; L Struillou; D Baron; H B Drugeon
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

6.  Activities of rifabutin, clarithromycin, and ethambutol against two virulent strains of Mycobacterium avium in a mouse model.

Authors:  S K Furney; P S Skinner; J Farrer; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

7.  Rifabutin and sparfloxacin but not azithromycin inhibit binding of Mycobacterium avium complex to HT-29 intestinal mucosal cells.

Authors:  L E Bermudez; L S Young; C B Inderlied
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

Review 8.  Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; A Fitton
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

9.  Vitamins A & D inhibit the growth of mycobacteria in radiometric culture.

Authors:  Robert J Greenstein; Liya Su; Sheldon T Brown
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.